baricitinib (Olumiant) Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate.
baricitinib (Olumiant) Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.
August 2023 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, August 7) published advice on five medicines.
September 2017 decisions news release The Scottish Medicines Consortium (SMC) has today published advice accepting four new medicines for use by NHSScotland.
June 2021 decisions news release Advice on five new medicines for use in conditions including advanced gastric cancer and chronic lymphocytic leukaemia has today (Monday 7 June) been published by the Scottish Medicines Consortium.
